For this grant period we plan to contribute 100 evaluable patients per year to SWOG protocol studies. Tumor categories in which we will have active participation are myeloma, breast, bladder, lymphoma and melanoma. Participation will be multidisciplinary. We will continue our active participation in analysis, survival and risk factor determination in first line therapy for multiple myeloma by being a major contributor to the proposed SWOG study comparing VMCP/VBAP with VAD (Vincristine, Adriamycin and Dexamethasone) and VMCP-Prednisone with or without Interferon as maintenance therapy. Participation in the pathology review of gastrointestinal malignancies and the adjunctive treatment of carcinoma of the colon with 5-FU infusion and/or Levamisole will be continued. We will participate in the proposed protocols involving early detection and/or prevention of malignancy proposed by the Cancer Control Research Committee. The use of Tumor Necrosis Factor in relapsing and resistant multiple myeloma will be prosposed. There will be increased activity in the use of Flow Cytometry and Cytogenetics and the evaluation of lymphomas and leukemias. We will continue working on the development of a pilot Computer Assisted Prospective Quality Assurance System.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA028862-10
Application #
3557010
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-01-01
Project End
1992-12-31
Budget Start
1990-01-01
Budget End
1990-12-31
Support Year
10
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Scott and White Memorial Hospital
Department
Type
DUNS #
076697960
City
Temple
State
TX
Country
United States
Zip Code
76504
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9
Scosyrev, Emil; Ely, Benjamin W; Messing, Edward M et al. (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693-9
Chu, David Z J; Hussey, Michael A; Alberts, David S et al. (2011) Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer 10:310-6
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Sonpavde, Guru; Goldman, Bryan H; Speights, V O et al. (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104-9
Dhodapkar, Madhav V; Hoering, Antje; Gertz, Morie A et al. (2009) Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 113:793-6
Swinnen, Lode J; Rankin, Cathryn; Carraway, Hetty et al. (2008) A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). J Neurooncol 86:353-8

Showing the most recent 10 out of 40 publications